Catalog No.
DHC83401
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
V-kappa
Clonality
Monoclonal
Target
CD28, TP44, T-cell-specific surface glycoprotein CD28
Concentration
0.51 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P10747
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
Lulizumab
Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model, PMID: 32898569
Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects, PMID: 27402064
Advances in the treatment of cutaneous lupus erythematosus, PMID: 27252259
Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699, PMID: 26442523
Costimulation blockade: the next generation., PMID:39882641
Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus., PMID:38050332
Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model., PMID:32898569
Pharmacokinetic, Pharmacodynamic, and Safety Profile of a Novel Anti-CD28 Domain Antibody Antagonist in Healthy Subjects., PMID:27402064
Advances in the treatment of cutaneous lupus erythematosus., PMID:27252259
Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699., PMID:26442523
For research use only. Not for human or drug use.
